Censavudine
Investigational new anti-HIV drug
- Investigational
- 1-[(2R,5R)-5-ethynyl-5-(hydroxymethyl)-2H-furan-2-yl]-5-methylpyrimidine-2,4-dione
- 634907-30-5
- 3008897
- 2278330
- 6IE83O6NGA
- D10550
- ChEMBL124363
- 209894
- DTXSID50212893
- Interactive image
- CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@](O2)(CO)C#C
InChI
- InChI=1S/C12H12N2O4/c1-3-12(7-15)5-4-9(18-12)14-6-8(2)10(16)13-11(14)17/h1,4-6,9,15H,7H2,2H3,(H,13,16,17)/t9-,12+/m1/s1
- Key:OSYWBJSVKUFFSU-SKDRFNHKSA-N
Censavudine (INN;[1] development code BMS-986001) is an investigational new drug being developed by Bristol Myers-Squibb for the treatment of HIV infection.[2][3] It was originally developed at Yale University.[4] It is still in an investigational phase of development as of 2023.[5]
Renaming
Until 2013, censavudine has been known as festinavir, but the name was changed to avoid confusion with HIV protease inhibitors which all bear class suffix "–navir" (e.g. tipranavir, lopinavir, saquinavir, etc.).[5]
References
- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed International Nonproprietary Names: List 110" (PDF). World Health Organization. pp. 409–410.
- ^ Wu VH, Smith RA, Masoum S, Raugi DN, Ba S, Seydi M, et al. (August 2017). "MK-8591 (4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture". Antimicrobial Agents and Chemotherapy. 61 (8). doi:10.1128/AAC.00744-17. PMC 5527656. PMID 28559249.
- ^ Gupta SK, McComsey GA, Lombaard J, Echevarría J, Orrell C, Avihingsanon A, et al. (January 2016). "Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial". The Lancet. HIV. 3 (1): e13-22. doi:10.1016/S2352-3018(15)00231-3. hdl:1805/10552. PMID 26762988.
- ^ Alcorn K (21 December 2010). "Bristol-Myers Squibb buys festinavir, new NRTI active against MDR HIV". aidsmap.com. aidsmap. Retrieved 24 June 2011.
- ^ a b PubChem. "Censavudine". pubchem.ncbi.nlm.nih.gov. Retrieved 2023-10-24.
- v
- t
- e
(Discovery and development)
(Integrase strand transfer inhibitors (INSTI))
(Discovery and development)
1st generation | |
---|---|
2nd generation |
inhibitors (RTIs)
Nucleoside and nucleotide (NRTI) | |||||
---|---|---|---|---|---|
Non-nucleoside (NNRTI) (Discovery and development) |
|
- Abacavir/lamivudine#
- Abacavir/dolutegravir/lamivudine°
- Abacavir/lamivudine/zidovudine
- Atazanavir/cobicistat
- Bictegravir/emtricitabine/tenofovir alafenamide°
- Cabotegravir/rilpivirine
- Darunavir/cobicistat
- Darunavir/cobicistat/emtricitabine/tenofovir alafenamide°
- Dolutegravir/emtricitabine/tenofovir alafenamide
- Dolutegravir/lamivudine°
- Dolutegravir/lamivudine/tenofovir alafenamide°
- Dolutegravir/lamivudine/tenofovir disoproxil°#
- Dolutegravir/rilpivirine
- Doravirine/lamivudine/tenofovir disoproxil
- Efavirenz/emtricitabine/tenofovir disoproxil#
- Efavirenz/lamivudine/tenofovir disoproxil#
- Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
- Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil
- Emtricitabine/tenofovir alafenamide
- Emtricitabine/rilpivirine/tenofovir alafenamide
- Emtricitabine/rilpivirine/tenofovir disoproxil
- Emtricitabine/tenofovir disoproxil#
- Lamivudine/nevirapine/stavudine
- Lamivudine/nevirapine/zidovudine
- Lamivudine/raltegravir
- Lamivudine/tenofovir disoproxil#
- Lamivudine/zidovudine#
- Lopinavir/ritonavir#
Uncoating inhibitors |
|
---|---|
Transcription inhibitors |
|
Translation inhibitors | |
BNAbs | |
Other | |
Failed agents |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e